Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
US Patent Number
8946151
Publication Date
2-3-2015
Abstract
A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in need of treatment thereof via convection-enhanced infusion using at least one implantable pump and at least one catheter. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal multiport brain catheters connected to one or more implantable pumps wherein the flow rate is pulsed.
Assignees
Northern Bristol N.H.S. Trust Frenchay Hospital, Bristol (GB), University of Kentucky Research Foundation, Lexington, KY (US), Amgen Inc., Thousand Oaks, CA (US)
Application Number
10/963,986
Filing Date
10/13/2004
Recommended Citation
Gill, Stephen S.; Gash, Don M.; and Gerhardt, Greg A., "Method of Treating Parkinson's Disease in Humans by Convection-Enhanced Infusion of Glial Cell-Line Derived Neurotrophic Factor to the Putamen" (2015). Neuroscience Faculty Patents. 7.
https://uknowledge.uky.edu/neurobio_patents/7
